TRANSDERMAL NICOTINE TREATMENT OF MILD COGNITIVE IMPAIRMENT (MCI)

轻度认知障碍 (MCI) 的透皮尼古丁治疗

• 批准号: 7608422
• 负责人: Paul S. Aisen
• 金额: $ 1.33万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608422
• 关键词: Clinical Trials; Cognition; Computer Retrieval of Information on Scientific Projects Database; Dementia; Diagnosis; Double-Blind Method; Funding; Goals; Grant; Institution; Label; Neurobehavioral Manifestations; Nicotine; Patients; Placebo Control; Placebos; Plant alkaloid; Randomized; Research; Research Personnel; Resources; Safety; Site; Source; Symptoms; Testing; United States National Institutes of Health; improved; mild neurocognitive impairment; non-smoking; normal aging; older patient

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. MCI is defined as a subjective and objective decline in cognition and function that does not meet criteria for a diagnosis of dementia and that represents a transitional state between the cognition of normal aging and mild dementia. The plant alkaloid nicotine may represent a promising agent to test for its ability to improve the cognitive symptoms of MCI and delay progression to dementia. The primary goal of this trial will be to establish the safety of long-term nicotine in non-smoking older patients with a secondary goal of examining whether nicotine will alleviate cognitive symptoms of MCI and whether this effect will be detectable by patients and clinicians. This study is a three-site 12-month pilot clinical trial of the safety and efficacy of transdermal nicotine in alleviating symptoms of MCI. The trial will consist of 6 months of randomized double-blind placebo-controlled treatment with nicotine or placebo followed by 6 months of open label nicotine treatment.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 MCI被定义为认知和功能的主观和客观下降，不符合诊断痴呆症的标准，并且代表了正常衰老和轻度痴呆的认知之间的过渡状态。 植物生物碱尼古丁可能代表一种有前途的药物，可以测试其改善MCI认知症状并延迟发展为痴呆症的能力。 该试验的主要目的是在不吸烟的老年患者中建立长期尼古丁的安全性，其次要目标是检查尼古丁是否会减轻MCI的认知症状，以及患者和临床医生是否可以检测到这种影响。这项研究是一项三个点的12个月前试验临床试验，是对透皮尼古丁在减轻MCI症状方面的安全性和功效的临床试验。 该试验将包括6个月的尼古丁或安慰剂的随机双盲安慰剂对照治疗，然后进行6个月的开放标签尼古丁治疗。